Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

February 4, 2009

Primary Completion Date

January 9, 2012

Study Completion Date

January 16, 2014

Conditions
Lung Cancer
Interventions
DRUG

carboplatin

Given IV

DRUG

cediranib maleate

Given orally

DRUG

paclitaxel

Given IV

OTHER

placebo

Given orally

Trial Locations (19)

CEP20231-050

Instituto Nacional de Cancer (INCA), Rio de Janeiro

01224-010

Instituto de Cancer Arnaldo Vieira de Carvalho, São Paulo

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V2S 0C2

BCCA - Abbotsford Centre, Abbotsford

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

P6B 0A8

Algoma District Cancer Program, Sault Ste. Marie

L2R 7C6

Niagara Health System, St. Catharines

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

N8W 2X3

Windsor Regional Cancer Centre, Windsor

H2W 1S6

McGill University - Dept. Oncology, Montreal

G1V 4G5

University Institute of Cardiology and, Québec

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK